[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ATE552832T1 - Antidepressivum-propharmaka - Google Patents

Antidepressivum-propharmaka

Info

Publication number
ATE552832T1
ATE552832T1 AT07751499T AT07751499T ATE552832T1 AT E552832 T1 ATE552832 T1 AT E552832T1 AT 07751499 T AT07751499 T AT 07751499T AT 07751499 T AT07751499 T AT 07751499T AT E552832 T1 ATE552832 T1 AT E552832T1
Authority
AT
Austria
Prior art keywords
antidepressant
propharmacies
prodrugs
prodrug
conjugated
Prior art date
Application number
AT07751499T
Other languages
English (en)
Inventor
Travis Mickle
Wendy Hirschelman Severs
Original Assignee
Shire Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Llc filed Critical Shire Llc
Application granted granted Critical
Publication of ATE552832T1 publication Critical patent/ATE552832T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542Carboxylic acids, e.g. a fatty acid or an amino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT07751499T 2006-02-24 2007-02-22 Antidepressivum-propharmaka ATE552832T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77621606P 2006-02-24 2006-02-24
PCT/US2007/004743 WO2007100668A2 (en) 2006-02-24 2007-02-22 Antidepressant prodrugs

Publications (1)

Publication Number Publication Date
ATE552832T1 true ATE552832T1 (de) 2012-04-15

Family

ID=38459574

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07751499T ATE552832T1 (de) 2006-02-24 2007-02-22 Antidepressivum-propharmaka

Country Status (5)

Country Link
US (1) US20110136742A1 (de)
EP (1) EP1991248B1 (de)
AT (1) ATE552832T1 (de)
CA (1) CA2643892A1 (de)
WO (1) WO2007100668A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8198268B2 (en) 2008-10-31 2012-06-12 Janssen Biotech, Inc. Tianeptine sulfate salt forms and methods of making and using the same
SG11201610547WA (en) * 2014-06-27 2017-01-27 Kao Corp Solid composition
JP2021505595A (ja) 2017-12-05 2021-02-18 サノビオン ファーマシューティカルズ インクSunovion Pharmaceuticals Inc. 結晶形およびその製造方法
SG11202005016SA (en) 2017-12-05 2020-06-29 Sunovion Pharmaceuticals Inc Nonracemic mixtures and uses thereof
US11160758B2 (en) 2019-06-04 2021-11-02 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3875137A (en) * 1973-04-20 1975-04-01 Searle & Co N-Substituted aspactyl peptide amids
AU710339B2 (en) * 1994-10-05 1999-09-16 Amarin Neuroscience Limited Treatment of multiple sclerosis (ms) and other demyelinating conditions using lofepramine in combination with l-phenylalanine, tyrosine or tryptophan and possibly a vitamin b12 compound
US6716452B1 (en) 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US7060708B2 (en) 1999-03-10 2006-06-13 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
CA2477038A1 (en) 2002-02-22 2003-09-04 New River Pharmaceuticals Use of peptide-drug conjugation to reduce inter-subject variability of drug serum levels
CA2540678C (en) 2003-09-30 2011-02-22 New River Pharmaceuticals Inc. Pharmaceutical compositions for prevention of overdose or abuse

Also Published As

Publication number Publication date
CA2643892A1 (en) 2007-09-07
EP1991248A4 (de) 2009-08-05
US20110136742A1 (en) 2011-06-09
WO2007100668A3 (en) 2008-09-12
EP1991248B1 (de) 2012-04-11
WO2007100668A2 (en) 2007-09-07
EP1991248A2 (de) 2008-11-19

Similar Documents

Publication Publication Date Title
CY1118454T1 (el) Πρωτοτυποι αναστολεις πυρρολιου της αναγωγασης s-νιτροζογλουταθειονης ως θεραπευτικοι παραγοντες
EA200802008A1 (ru) Фармацевтические композиции
ATE528989T1 (de) Kristalline feste rasagilin-base
BR112012014082A2 (pt) composições e métodos que compreendem variantes de protease
UY30319A1 (es) Formulaciones de inhibidores de dpp iv
BRPI0710508B8 (pt) composição de pepticorpo terapêutico liofilizado estável, kit para preparar uma composição farmacêutica aquosa, e métodos para fabricar um pepticorpo terapêutico liofilizado e para preparar uma composição de pepticorpo terapêutico reconstituído
NI201000055A (es) 2' - fluoro - 2' - desoxitetrahidrouridinas como inhibidores de citidina desaminasa.
HN2006011218A (es) Composiciones de tigeciclina y métodos de preparación
ATE502921T1 (de) Substituierte indole
NO20090596L (no) Antivirale fosfinatforbindelser
NO20074823L (no) Rasagilin-formuleringer med forbedret innholdsensartethet
MX2009004862A (es) Estabilizacion de vacunas por liofilizacion.
EA201190306A1 (ru) Улучшенная липидная композиция
EA201170227A1 (ru) Имидазолкарбоксамиды
BRPI1015043A2 (pt) derivados de diazahomoadamantano e métodos de uso dos mesmos
EA201001639A1 (ru) Композиции и способы их получения и применения
GT200600117A (es) Nuevos compuestos farmaceuticos
ATE509931T1 (de) Azaadamantanester- und carbamatderivate sowie anwendungsverfahren dafür
DE502006005053D1 (de) Spritzbare akustikmassen
TN2009000510A1 (en) Extended release formulation of nevirapine
UA86119C2 (ru) Амидные пролекарства гемцитабина, их композиции и применение
ATE552832T1 (de) Antidepressivum-propharmaka
TR201109686T2 (tr) Olmesartan'ın Farmasötik Bileşimleri.
NO20091386L (no) Fenyloksyanilinderivater
CY1113835T1 (el) Δραση των εκχυλισματων του φυτου cissampelos pareira εναντι του δαγκειου πυρετου